AstraZeneca PLC has decided to stop INEXAS, the Phase IIa trial to investigate the effects on asthma patients of the inhaled Interferon beta-1a compound AZD9412 in-licensed from Synairgen PLC, because a mid-way analysis showed too few participants reported severe exacerbations, the primary endpoint target, making conclusions difficult.
INEXAS was initiated in June 2015 to study if inhaled Interferon beta-1a is safe and tolerated, and can prevent or...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
